CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi:10.3322/caac.2133226742998
   PubMed Web of Science ®Google Scholar
• Mirakabad FST, Nejati-Koshki K, Akbarzadeh A, et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15(2):517–535. doi:10.7314/apjcp.2014.15.2.51724568455
   PubMedGoogle Scholar
• Mukherjee B, Das S, Chakraborty S, et al. Potentials of polymeric nanoparticle as drug carrier for cancer therapy: with a special reference to pharmacokinetic parameters. Curr Drug Metab. 2015;15(6):565–580. doi:10.2174/1389200215666140605150703
   Web of Science ®Google Scholar
• Alatrash G, Molldrem JJ. Tumor-associated antigens In: Socié G, Blazar BR editors. Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation.Models in Discovery and Translation. Academic Press ISBN: 978-0-12-416004-0; 2013 143–164.
   Google Scholar
• Mukherjee B. Nanosize drug delivery system. Curr Pharm Biotechnol. 2013;14(15):1221.25106648
   PubMed Web of Science ®Google Scholar
• Xi J, Li M, Jing B, et al. Long-circulating amphiphilic doxorubicin for tumor mitochondria specific targeting. ACS Appl Mater Interfaces. 2018;10:43482−43492. doi:10.1021/acsami.8b1739930479120
   PubMed Web of Science ®Google Scholar
• Lv S, Li M, Tang Z, et al. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Acta Biomater. 2013;9(12):9330–9342. doi:10.1016/j.actbio.2013.08.01523958784
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet. 2003;42(5):419–436. doi:10.2165/00003088-200342050-0000212739982
   PubMed Web of Science ®Google Scholar
• Criscitiell C. Tumor-associated antigens in breast cancer. Breast Care. 2012;7:262–266. doi:10.1159/00034216423904827
   PubMedGoogle Scholar
• Wold ED, Smider VV, Felding BH. Antibody therapeutics in oncology. Immunotherapy. 2016;2(1):1–18. doi:10.4172/2471-9552.1000108
   Google Scholar
• Mukherjee B, Satapathy BS, Mondal L, Dey NS, Maji R. Potentials and challenges of active targeting at the tumor cells by engineered polymeric nanoparticles. Curr Pharm Biotechnol. 2013;14(15):1250–1263.24910012
   PubMed Web of Science ®Google Scholar
• Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers. 2019;11:640. doi:10.3390/cancers11050640
   PubMed Web of Science ®Google Scholar
• Fahmy TM, Fong PM, Goyal A, Saltzman WM. Targeted for drug delivery. Nanotoday. 2005;8(8):18–26.
   Google Scholar
• Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Hindawi Publishing Corporation. 2014;2014:9 Article ID 852748.
   Google Scholar
• Breastcancer. Pennsylvania: HER2 status. 2019 Available from: https://www.breastcancer.org/symptoms/diagnosis/her2 Accessed 812, 2019.
   Google Scholar
• Biolegend. United States: FITC anti-human CD340 (erbB2/HER-2) Antibody. 2019 Available from https://www.biolegend.com/en-us/products/fitc-anti-human-cd340-erbb2-her-2-antibody-3765. Accessed 814, 2019.
   Google Scholar
• Maji R, Dey NS, Satapathy BS, Mukherjee B, Mondal S. Preparation and characterization of tamoxifen citrate loaded nanoparticles for breast cancer therapy. Int J Nanomedicine. 2014;9:3107–3118. doi:10.2147/IJN.S6353525028549
   PubMed Web of Science ®Google Scholar
• Thamake SI, Raut SL, Ranjan AP, Gryczynski Z, Vishwanatha JK. Surface functionalization of PLGAnanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy. Nanotechnology. 2011;22(3):035101–0351011. doi:10.1088/0957-4484/22/3/03510121149963
   PubMedGoogle Scholar
• Das PJ, Paul P, Mukherjee B, et al. Pulmonary delivery of voriconazole loaded nanoparticles providing a prolonged drug level in lungs: a promise for treating fungal infection. Mol Pharm. 2015;12(8):2651–2664. doi:10.1021/acs.molpharmaceut.5b0006425941882
   PubMed Web of Science ®Google Scholar
• Dutta L, Mukherjee B, Chakraborty T, et al. Lipid-based nanocarrier efficiently delivers highly water soluble drug across the blood-brain barrier into brain. Drug Deliv. 2018;25(1):504–516. doi:10.1080/10717544.2018.147496729426257
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Mondal L, Mukherjee B, Dutta L, Ehsan I, Debnath MC. Apigenin loaded nanoparticle delayed development of hepatocellular carcinoma in rats. Nanomedicine. 2018;14(6):1905–1917. doi:10.1016/j.nano.2018.05.01129802937
   PubMed Web of Science ®Google Scholar
• Mukerjee A, Ranjan AP, Vishwanatha JK, Helson L. Non-covalent surface integration: optimizing a novel technique for preparing targeted polymeric nanoparticles for cancer therapeutics. Int J Nanotechnol. 2014;11(5/6/7/8):676–685. doi:10.1504/IJNT.2014.060590
   Web of Science ®Google Scholar
• Chen H, Gao J, Lu Y, et al. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Release. 2008;128(3):209–216. doi:10.1016/j.jconrel.2008.03.01018450313
   PubMed Web of Science ®Google Scholar
• Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with a monoclonal antibody. J Control Release. 2007;120(1–2):18–26. doi:10.1016/j.jconrel.2007.03.01217509712
   PubMed Web of Science ®Google Scholar
• Das K, Prasad R, Singh A, et al. Protease-activated receptor 2 promotes actomyosin dependent transforming microvesicles generation from human breast cancer. Mol Carcinog. 2018;57(12):1707–1722. doi:10.1002/mc.2289130129687
   PubMedGoogle Scholar
• Mandal D, Shaw TK, Dey G, et al. Preferential hepatic uptake of paclitaxel-loaded poly-(D-L-lactide-co-glycolide) nanoparticles- A possibility for hepatic drug targeting: pharmacokinetics and biodistribution. Int J Biol Macromol. 2018;112:818–830. doi:10.1016/j.ijbiomac.2018.02.02129421493
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005;2(5):373–383. doi:10.1021/mp050032z16196490
   PubMed Web of Science ®Google Scholar
• Zeng X, Morgenstern R, Nyström AM. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization of breast cancer cells by circumventing GST-Mediated drug resistance. Biomaterials. 2014;35(4):1227–1239. doi:10.1016/j.biomaterials.2013.10.04224210875
   PubMed Web of Science ®Google Scholar
• Parveen S, Sahoo SK. Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma. Cancer Nano. 2010;1(1–6):47–62. doi:10.1007/s12645-010-0006-0
   PubMedGoogle Scholar
• Ding L, Tian C, Feng S, Fida G, Zhang C, Ma Y. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics. 2015;5(4):378–398. doi:10.7150/thno.1008425699098
   PubMed Web of Science ®Google Scholar
• Peterson QP, Goode DR, West DC, Botham RC, Hergenrother PJ. Preparation of the caspase-3/7 substrate Ac-DEVD-pNA by solution-phase peptide synthesis. Nat Protoc. 2010;5(2):294–302. doi:10.1038/nprot.2009.14920134429
   PubMedGoogle Scholar
• Ma W, Wang J, Guo Q, Tu P. Simultaneous determination of doxorubicin and curcumin in rat plasma by LC–MS/MS and its application to pharmacokinetic study. J Pharm Biomed Anal. 2015;111:215–221. doi:10.1016/j.jpba.2015.04.00725910045
   PubMedGoogle Scholar
• Park J, Fong PM, Lu J, et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine. 2009;5(4):410–418. doi:10.1016/j.nano.2009.02.00219341815
   PubMed Web of Science ®Google Scholar
• Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197(4299):165–167. doi:10.1126/science.877547877547
   PubMed Web of Science ®Google Scholar
• Jain AK, Swarnakar NK, Das M, et al. Augmented anticancer efficacy of doxorubicin-loaded nanoparticles after oral administration in a breast cancer induced animal model. Mol Pharm. 2011;8(4):1140–1151. doi:10.1021/mp200011f21557558
   PubMed Web of Science ®Google Scholar
• Choi WI, Lee JH, Kim JY, et al. Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab. Nanomedicine. 2015;11(2):359–368. doi:10.1016/j.nano.2014.09.00925262581
   PubMed Web of Science ®Google Scholar
• Gaonkar RH, Ganguly S, Dewanjee S, et al. Garcinol loaded vitamin E TPGS emulsified PLGA nanoparticles: preparation, physicochemical characterization, in vitro and in vivo studies. Sci Rep. 2016;7(530):1–14.
   Google Scholar
• Satapathy BS, Mukherjee B, Baishya R, Debnath MC, Dey NS, Maji R. Lipid nanocarrier based transport of docetaxel across the blood-brain barrier. RSC Adv. 2016;6(88):85261–85274. doi:10.1039/C6RA16426A
   Web of Science ®Google Scholar
• Chakraborty S, Ehsan I, Mukherjee B, et al. Therapeutic potential of andrographolide-loaded nanoparticles on a murine asthma model. Nanomedicine. 2019;20:102006. doi:10.1016/j.nano.2019.04.00931059793
   PubMedGoogle Scholar
• Chung YI, Kim JC, Kim YH, et al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting. J Control Release. 2010;143(3):374–382. doi:10.1016/j.jconrel.2010.01.017 Epub 2010 Jan 25.20109508
   PubMed Web of Science ®Google Scholar
• Jiang D, Lynch C, Medeiros CB, Liedtke M, Bam R, Tam AB. Identification of doxorubicin as an inhibitor of the ire1α-xbp1 axis of the unfolded protein response. Sci Rep. 2016;6:33353. doi:10.1038/srep3335327634301
   PubMedGoogle Scholar
• Khemani M, Sharon M, Sharon M. pH-Dependent Encapsulation of Doxorubicin in PLGA. Ann Biol Res. 2012;3(9):4414–4441.
   Google Scholar
• Cirstoiu-Hapca A, Buchegger F, Bossy L, Kosinski M, Gurny R, Delie F. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immuno nanoparticles and in vitro functional studies on target cells. Eur J Pharm Sci. 2009;38(3):230–237. doi:10.1016/j.ejps.2009.07.00619632322
   PubMedGoogle Scholar
• Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi AA, Dinarvand R. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int J Nanomedicine. 2011;6:1977–1990. doi:10.2147/IJN.S2564621976974
   PubMed Web of Science ®Google Scholar
• Kim S-W, Khang D. Multiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiency. Int J Nanomedicine. 2015;10:3989–4008.26124658
   PubMed Web of Science ®Google Scholar
• Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78–88. doi:10.1111/j.1365-2567.2005.02268.x16423043
   PubMed Web of Science ®Google Scholar
• Merlin JL, Barberi-Heyob M, Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines. Ann Oncol. 2002;13(11):1743–1748. doi:10.1093/annonc/mdf26312419746
   PubMedGoogle Scholar
• Siddharth S, Nayak A, Nayak D, Bindhani BK, Kundu CN. Chitosan-Dextran sulfate coated doxorubicin loaded PLGA-PVA nanoparticles caused apoptosis in doxorubicin resistance breast cancer cells through induction of DNA damage. Sci Rep. 2017;7:2143. doi:10.1038/s41598-017-02134-z28526868
   PubMedGoogle Scholar
• Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A. Activation and caspase-mediated inhibition of PARP: A molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell. 2002;13(3):978–988. doi:10.1091/mbc.01-05-027211907276
   PubMed Web of Science ®Google Scholar
• Chaitanya G, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal. 2010;8(31):1–11. doi:10.1186/1478-811X-8-120181064
   PubMedGoogle Scholar
• Semete B, Booysen L, Lemmer Y, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine. 2010;6(5):662–671. doi:10.1016/j.nano.2010.02.00220230912
   PubMed Web of Science ®Google Scholar
• Navarro SM, Morgan TW, Astete CE, et al. Biodistribution and toxicity of orally administered poly(lactic-co-glycolic) acid nanoparticles to F344 rats for 21 days. Nanomedicine. 2016;11(13):1653–1669. doi:10.2217/nnm-2016-023327347781
   PubMedGoogle Scholar